Abstract
Background: Hidradenitis suppurativa (HS) is characterized by chronic, suppurative abscesses, sinus tracts, and fistulas affecting the axilla, groin, and perianal region resulting from hyperkeratosis and occlusion of the terminal hair follicle. Objective: This report highlights the use of biologic agents for the treatment of recalcitrant HS. Method: We report on a 48-year-old male with a 15-year history of refractory perianal-inguinal-buttock HS who, despite receiving numerous surgical drainages and traditional medical treatmentfor HS, still had severe pain. After trialing etanercept and infliximab with methotrexate, the patient had marked improvement with adalimumab. Aliterature review of biologies therapywas also performed. Results: After trialing m any traditional therapies, we found that adalimumab appears to be the mosteffective treatment modalityfor our patient. A literature search revealed 53 articles on biologies therapy in HS. These articles are summarized. Discussion: Biologic agents have been shown to have variable results in the treatment of refractory HS. Enough lowgrade evidence has been accumulated to make the use of these agents suitable in HS. Until more clinical trials are performed on this topic, physicians should use clinical judgment when treating HS with biologic agents and be cautious by watching for significant adverse effects.
| Original language | English (US) |
|---|---|
| Journal | Journal of Cutaneous Medicine and Surgery |
| Volume | 17 |
| Issue number | SUPPL.1 |
| State | Published - Jul 1 2013 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Dermatology
- Surgery
Cite this
Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision : A review of biologies therapy. / Samycia, Michael; Brassard, Alain.
In: Journal of Cutaneous Medicine and Surgery, Vol. 17, No. SUPPL.1, 01.07.2013.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision
T2 - A review of biologies therapy
AU - Samycia, Michael
AU - Brassard, Alain
PY - 2013/7/1
Y1 - 2013/7/1
N2 - Background: Hidradenitis suppurativa (HS) is characterized by chronic, suppurative abscesses, sinus tracts, and fistulas affecting the axilla, groin, and perianal region resulting from hyperkeratosis and occlusion of the terminal hair follicle. Objective: This report highlights the use of biologic agents for the treatment of recalcitrant HS. Method: We report on a 48-year-old male with a 15-year history of refractory perianal-inguinal-buttock HS who, despite receiving numerous surgical drainages and traditional medical treatmentfor HS, still had severe pain. After trialing etanercept and infliximab with methotrexate, the patient had marked improvement with adalimumab. Aliterature review of biologies therapywas also performed. Results: After trialing m any traditional therapies, we found that adalimumab appears to be the mosteffective treatment modalityfor our patient. A literature search revealed 53 articles on biologies therapy in HS. These articles are summarized. Discussion: Biologic agents have been shown to have variable results in the treatment of refractory HS. Enough lowgrade evidence has been accumulated to make the use of these agents suitable in HS. Until more clinical trials are performed on this topic, physicians should use clinical judgment when treating HS with biologic agents and be cautious by watching for significant adverse effects.
AB - Background: Hidradenitis suppurativa (HS) is characterized by chronic, suppurative abscesses, sinus tracts, and fistulas affecting the axilla, groin, and perianal region resulting from hyperkeratosis and occlusion of the terminal hair follicle. Objective: This report highlights the use of biologic agents for the treatment of recalcitrant HS. Method: We report on a 48-year-old male with a 15-year history of refractory perianal-inguinal-buttock HS who, despite receiving numerous surgical drainages and traditional medical treatmentfor HS, still had severe pain. After trialing etanercept and infliximab with methotrexate, the patient had marked improvement with adalimumab. Aliterature review of biologies therapywas also performed. Results: After trialing m any traditional therapies, we found that adalimumab appears to be the mosteffective treatment modalityfor our patient. A literature search revealed 53 articles on biologies therapy in HS. These articles are summarized. Discussion: Biologic agents have been shown to have variable results in the treatment of refractory HS. Enough lowgrade evidence has been accumulated to make the use of these agents suitable in HS. Until more clinical trials are performed on this topic, physicians should use clinical judgment when treating HS with biologic agents and be cautious by watching for significant adverse effects.
UR - http://www.scopus.com/inward/record.url?scp=84885788328&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885788328&partnerID=8YFLogxK
M3 - Review article
VL - 17
JO - Journal of Cutaneous Medicine and Surgery
JF - Journal of Cutaneous Medicine and Surgery
SN - 1203-4754
IS - SUPPL.1
ER -